C12N 9/6451
Coagulation factor xiia
Official title: {Coagulation factor XIIa (3.4.21.38)}
C12N9/6451 (Coagulation factor xiia) appears on 33 US grants and 67 published applications in this corpus.
Search patents in C12N- Granted patents
- 33
- Published applications
- 67
- Assignees
- 13
- Inventors
- 43
- Latest grant
- 31 Jan 2023
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 1 |
| 2004 | 0 | 2 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 1 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 2 |
| 2014 | 0 | 30 |
| 2015 | 13 | 8 |
| 2016 | 5 | 5 |
| 2017 | 5 | 2 |
| 2018 | 2 | 3 |
| 2019 | 4 | 4 |
| 2020 | 2 | 1 |
| 2021 | 0 | 3 |
| 2022 | 0 | 0 |
| 2023 | 1 | 0 |
| 2024 | 0 | 2 |
| 2025 | 0 | 2 |
| 2026 | 0 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins31 Jan 2023US 11,564,998 B2ModernaTX, Inc.
- Modified Polynucleotides for the production of biologics and proteins associated with human disease15 Sep 2020US 10,772,975 B2ModernaTX, Inc.
- In vivo production of proteins10 Mar 2020US 10,583,203 B2ModernaTX, Inc.
- Modified polynucleotides10 Dec 2019US 10,501,512 B2ModernaTX, Inc.
- In vivo production of proteins3 Dec 2019US 10,493,167 B2ModernaTX, Inc.
- In vivo production of proteins25 Jun 2026US 2026/0174909 A1ModernaTX, Inc.
- Urokinase-type plasminogen activator receptor binding peptides and methods of use19 Jun 2025US 2025/0197838 A1Case Western Reserve University
- Modified polynucleotides for the production of biologics and proteins associated with human disease16 Jan 2025US 2025/0018062 A1Moderna TX, Inc.
- Modified polynucleotides for the production of proteins associated with human disease3 Oct 2024US 2024/0327476 A1ModernaTX, Inc.
- Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins25 Apr 2024US 2024/0131193 A1Modema TX, Inc.
Most cited
By later US patents
- Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins198US 9,303,079 B2Moderna Therapeutics, Inc. · 2016
- Modified polynucleotides for the production of biologics and proteins associated with human disease196US 8,999,380 B2Moderna Therapeutics, Inc. · 2015
- Modified polynucleotides for treating protein deficiency194US 9,061,059 B2Moderna Therapeutics, Inc. · 2015
- Modified polynucleotides encoding basic helix-loop-helix family member E41125US 9,107,886 B2Moderna Therapeutics, Inc. · 2015
- Modified polynucleotides encoding copper metabolism (MURR1) domain containing 1124US 9,095,552 B2Moderna Therapeutics, Inc. · 2015